Table 3.

Association between SNPs and tumor grade among 267 women with invasive pre menopausal breast cancer in Nurses’ Health Study II

Gene	SNP	Minor allele	Major allele	MAF	Grade 2 versus 1 (N = 123 + 42)		Grade 3 versus 1 (N = 102 + 42)
					OR	P	OR	P
LEPR	rs4592284	G	C	0.43	1.50 (0.88–2.55)	0.13	1.32 (0.78–2.25)	0.30
LEPR	rs4655762	A	G	0.32	1.12 (0.64–1.96)	0.70	0.86 (0.49–1.53)	0.62
LEPR	rs2148683	G	A	0.47	0.93 (0.57–1.52)	0.77	0.88 (0.51–1.50)	0.63
LEPR	rs7540807	C	A	0.1	0.41 (0.20–0.87)	0.02c	0.49 (0.23–1.07)	0.08
LEPR	rs913199	A	C	0.45	0.62 (0.36–1.04)	0.07	0.62 (0.35–1.08)	0.09
LEPR	rs9436729	C	A	0.47	0.59 (0.35–1.01)	0.05	0.58 (0.33–1.03)	0.06
LEPR	rs17127601	G	A	0.14	0.36 (0.18–0.71)	0.003c	0.58 (0.30–1.13)	0.11
LEPR	rs3790436	C	G	0.44	0.75 (0.45–1.26)	0.28	0.65 (0.37–1.15)	0.14
LEPR	rs3806318	G	A	0.25	0.60 (0.34–1.05)	0.08	0.55 (0.30–1.00)	0.049c
LEPR	rs12145690	C	A	0.44	0.97 (0.58–1.62)	0.91	0.74 (0.41–1.36)	0.34
LEPR	rs4655802	G	A	0.42	1.02 (0.61–1.69)	0.94	1.09 (0.62–1.91)	0.78
LEPR	rs9436738	A	G	0.13	1.19 (0.55–2.54)	0.66	1.52 (0.67–3.44)	0.32
LEPR	rs9436740	A	T	0.28	1.05 (0.57–1.92)	0.88	0.84 (0.45–1.56)	0.58
LEPR	rs3790433	A	G	0.26	0.54 (0.30–0.97)	0.04c	0.51 (0.28–0.94)	0.03c
LEPR	rs17127618	G	C	0.15	0.48 (0.26–0.88)	0.02c	0.56 (0.29–1.07)	0.08
LEPR	rs9436301	G	A	0.24	0.62 (0.35–1.10)	0.10	0.59 (0.33–1.08)	0.09
LEPR	rs9436302a	A	G	0.21	0.58 (0.32–1.05)	0.07	0.66 (0.36–1.22)	0.19
LEPR	rs1887285	G	A	0.09	1.48 (0.59–3.75)	0.41	0.97 (0.38–2.50)	0.96
LEPR	rs1045895	A	G	0.4	0.90 (0.55–1.50)	0.69	0.92 (0.52–1.62)	0.77
LEPR	rs6657868	A	G	0.38	1.74 (0.99–3.06)	0.05	2.09 (1.13–3.87)	0.02c
LEPR	rs6704167	T	A	0.43	0.84 (0.50–1.41)	0.51	0.76 (0.44–1.30)	0.32
LEPR	rs7513047	A	G	0.48	0.81 (0.47–1.41)	0.46	0.77 (0.43–1.38)	0.38
LEPR	rs11808888a	A	G	0.14	0.44 (0.22–0.87)	0.02c	0.42 (0.20–0.85)	0.02c
LEPR	rs6672331	C	G	0.03	1.36 (0.25–7.52)	0.73	1.15 (0.16–8.35)	0.89
LEPR	rs11208659	G	A	0.08	1.02 (0.39–2.65)	0.98	1.09 (0.40–2.91)	0.87
LEPR	rs1627238a	A	G	0.17	0.60 (0.31–1.14)	0.12	0.49 (0.25–0.96)	0.04c
LEPR	rs1171279a	A	G	0.25	0.71 (0.38–1.30)	0.26	0.59 (0.32–1.08)	0.08
LEPR	rs6697315a	G	A	0.35	1.44 (0.82–2.55)	0.21	1.92 (1.03–3.58)	0.04c
LEPR	rs10158279a	A	C	0.49	0.84 (0.50–1.42)	0.52	0.45 (0.25–0.79)	0.006c
LEPR	rs1137100a,b	G	A	0.27	1.97 (0.99–3.89)	0.05	2.67 (1.31–5.47)	0.007c
LEPR	rs3790429	A	T	0.17	1.24 (0.65–2.37)	0.51	0.65 (0.33–1.30)	0.23
LEPR	rs6588152	A	T	0.21	0.72 (0.38–1.38)	0.33	1.18 (0.65–2.15)	0.59
LEPR	rs1137101a	G	A	0.46	1.43 (0.84–2.43)	0.19	2.45 (1.40–4.31)	0.002d
LEPR	rs4655537a	A	G	0.36	0.51 (0.30–0.87)	0.01c	0.42 (0.23–0.75)	0.004c
LEPR	rs3762274	G	A	0.39	1.30 (0.76–2.20)	0.34	1.86 (1.05–3.31)	0.035c
LEPR	rs11585329	A	C	0.16	1.11 (0.53–2.34)	0.78	1.32 (0.62–2.85)	0.47
LEPR	rs8179183	C	G	0.18	1.40 (0.71–2.74)	0.34	0.77 (0.38–1.59)	0.48
LEPR	rs6690625	C	A	0.2	1.65 (0.81–3.34)	0.17	2.03 (0.95–4.35)	0.07
LEPR	rs10889569	A	T	0.38	1.77 (1.02–3.06)	0.04c	1.33 (0.77–2.30)	0.31
LEPR	rs1805096	A	G	0.38	1.69 (0.99–2.89)	0.06	1.27 (0.74–2.18)	0.38
LEP	rs4731420	C	G	0.18	1.53 (0.72–3.24)	0.27	1.61 (0.78–3.32)	0.20
LEP	rs10954172	A	G	0.3	1.20 (0.66–2.19)	0.54	1.25 (0.71–2.21)	0.44
LEP	rs791600	A	G	0.41	0.77 (0.46–1.30)	0.33	0.55 (0.32–0.95)	0.03c
LEP	rs10487506	A	G	0.44	0.91 (0.55–1.49)	0.70	0.69 (0.42–1.13)	0.14
LEP	rs10244329	A	T	0.5	1.35 (0.80–2.27)	0.26	1.38 (0.84–2.28)	0.21
LEP	rs7795794	A	G	0.07	0.53 (0.20–1.39)	0.20	0.82 (0.33–2.03)	0.66
LEP	rs11760956	A	G	0.37	1.32 (0.73–2.38)	0.37	1.32 (0.75–2.32)	0.34
LEP	rs2071045	G	A	0.24	1.19 (0.66–2.16)	0.57	0.68 (0.35–1.33)	0.26
LEP	rs4731429	A	G	0.46	0.92 (0.54–1.57)	0.76	1.21 (0.71–2.08)	0.49
LEP	rs10954176	G	A	0.47	0.84 (0.51–1.38)	0.49	0.87 (0.51–1.48)	0.60
					Permutation P = 0.09		Permutation P = 0.04

Grade 1 well differentiated, Grade 2 moderately differentiated; Grade 3 poorly differentiated

^a9 SNPs associated with plasma soluble leptin receptor in a GWAS study with P value < 5 × 10⁻⁸

^bThe rs1137100 was previously reported to be associated with tumor size

^cP<.05, but not significant after multiple testing adjustment by 2,000 permutation

^dSignificant after multiple testing adjustment by 2,000 permutation